Chief Oncology Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

European Commission Approves Pfizer s ELREXFIO® for Relapsed and Refractory Multiple Myeloma -December 08, 2023 at 07:56 am EST

Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial ELREXFIO is an off-the-shelf ,.

United kingdomAl hamedChris boshoffMyeloma research foundationPfizer incExchange commissionHealthcare products regulatory agencyEnd results programDrug administrationApproval programCommittee for medicinal products human useNational cancer instituteEuropean medicines agencyEuropean commissionOncology researchWorld health organization

Pfizer (PFE) Announces European Commission Approves ELREXFIO for Relapsed and Refractory Multiple Myeloma

Pfizer (PFE) Announces European Commission Approves ELREXFIO for Relapsed and Refractory Multiple Myeloma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Chris boshoffEuropean commissionCommittee for medicinal products human useOncology researchPfizer incEuropean medicines agencyChief oncology researchDevelopment officerExecutive vice presidentMedicinal productsHuman use

EU Commission OKs Pfizer s ELREXFIO for Multiple Myeloma

EU Commission OKs Pfizer s ELREXFIO for Multiple Myeloma
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United kingdomChris boshoffDrug administrationCommittee for medicinal products human useEuropean medicines agencyEuropean commissionOncology researchPfizer incApproval programHealthcare products regulatory agencyChief oncology researchDevelopment officerExecutive vice presidentMedicinal productsHuman useAccelerated approval program

U S FDA Approves Pfizer, Astellas XTANDI for Early Prostate Cancer

U S FDA Approves Pfizer, Astellas XTANDI for Early Prostate Cancer
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesAhsan arozullahNaoki okamuraCourtney buglerChris boshoffHead of oncology developmentOncology researchDrug administrationAstellas pharma incPfizer incEuropean medicines agencyAmerican urological association annual meetingCarolina urologic research centerNew drug applicationPriority reviewFast track

Pfizer and Astellas XTANDI® Approved by U S FDA in Earlier Prostate Cancer Treatment Setting

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that the companies.

United statesChris boshoffNaoki okamuraAhsan arozullahCourtney buglerHead of oncology developmentAmerican urological association annual meetingAstellas pharma incDrug administrationOncology researchAmerican society of clinical oncologyCarolina urologic research centerPfizer incExchange commissionEuropean unionPrnewswire astellas pharma inc